Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LIM domain kinase 1 (LIMK1) and LIM domain kinase 2 (LIMK2) are closely related cytoplasmic kinases that play a central role in modulating actin cytoskeleton dynamics through phosphorylation and inactivation of cofilin, an actin depolymerizing factor. Both LIMK1 and LIMK2 possess N-terminal LIM domains (involved in protein-protein interactions), an adjacent PDZ domain, a serine/proline-rich region, and a C-terminal kinase domain that confers dual specificity for serine/threonine and tyrosine residues. They act downstream of Rho-family GTPases and are key effectors in multiple signal transduction pathways, regulating cellular processes such as migration, proliferation, division, and neuronal differentiation. Dysregulation of LIMKs is implicated in various pathologies, notably cancer progression and metastasis, and certain neurological diseases. Both LIMK1 and LIMK2 have distinct, but overlapping, tissue expression patterns and subcellular localizations, contributing to differential biological roles. The proteins are recognized as promising therapeutic targets, and several small-molecule inhibitors have been developed to disrupt their activity in disease contexts.
LIMK inhibitors typically block kinase activity, preventing phosphorylation/inactivation of cofilin, thereby destabilizing actin cytoskeleton and affecting cell migration, proliferation, and invasion
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LIM domain kinase 1 (LIMK1), LIM domain kinase 2 (LIMK2) (LIMK1, LIMK2).